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Abstract: 
Purpose Peptides derived from the Domain 1 of the adhesion molecule ICAM-1(1-21) are being 
developed as targeting ligands for LFA-1 receptors expressed on activated T-cells.  This work 
aims to elucidate the binding and internalization of ICAM-1-derived cyclic peptides (cIBL, cIBC, 
and cIBR) to LFA-1.   
Methods 96-well plates coated with soluble LFA-1 (sLFA-1) were used to characterize the 
binding of FITC-labeled peptide.  An anti-CD11a antibody to the I-domain of LFA-1 was used to 
inhibit the binding of these peptides, which was quantified using a fluorescence plate reader. 
An unrelated FITC-labeled cyclic peptide was used as a negative control and PE-labeled anti-
CD11a antibodies (PE-R3.2 and PE-R7.1) were used as positive controls.  Peptide binding to cell 
surface LFA-1 was visualized using co-localization of FITC-cIBR peptide and PE-labeled anti-CD18 
antibody (LFA-1 β-subunit) on SKW-3 T-cells by fluorescent microscopy. Inhibition of ICAM-1-
binding to LFA-1 by peptides was evaluated using a Biacore assay.  Binding and internalization 
of FITC-labeled peptides was evaluated by flow cytometry and confocal microscopy at 4 and 
37ºC.   
Results These FITC-labeled cyclic peptides bind to sLFA-1 and can be blocked by an anti-CD11a 
antibody to the I-domain, suggesting that their binding site is on the I-domain of LFA-1. The 
FITC-cIBR peptide was localized with an anti-CD18 antibody on the surface of T-cells, indicating 
that the FITC-cIBR peptide binds to LFA-1 on the cell surface.  Flow cytometry and confocal 
microscopy demonstrated that FITC-labeled peptides were internalized in temperature 
dependent manner.  Biacore analysis, demonstrated these peptides did not inhibit sICAM-1 
from binding to immobilized sLFA-1. However, the binding properties of the soluble forms of 
LFA-1 and ICAM-1 may not correlate to their interaction at the cell surface.   
Conclusion Cyclic ICAM-1 derived peptides (cIBL, cIBC, and cIBR) bind to the I-domain of LFA-1, 
and are internalized by LFA-1 receptors on the surface of T-cells. Therefore, these peptides 
could be utilized to target and deliver drugs to the cytoplasmic domain of T-cells. 
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INTRODUCTION 
Autoimmune diseases involve the activation and proliferation of T-cells that react to "self" 
antigens. Activated T-cells secrete cytokines to recruit other cells for engaging in the immune 
response. Activation of T-cells requires two different signals. The first signal (Signal-1) is mediated by 
the interaction between the T-cell receptor (TCR) on T-cells and an MHC:peptide complex on the 
surface of antigen-presenting cells (APC) such as B-cells or dendritic cells [1]. The second or co-
stimulatory signal (Signal-2) is delivered by several different pairs of molecules at the interface 
between T-cells and APC, including the interaction between leukocyte function-associated antigen-1 
(LFA-1) on T-cells and intercellular adhesion molecule-1 (ICAM-1) on the APC [1].  At the interface of 
T-cells and APC, these receptor/ligand pairs, can form a supra-molecular complex within a 
specialized cell-cell junction called the "immunological synapse" [2, 3].  The formation of this 
synapse has been followed by observing the dynamic movements of fluorescently-labeled MHC-II-
peptide complex and ICAM-1 on artificial planar membranes after the addition of T-cells [2]. Initially, 
TCR/MHC-peptide complexes (Signal-1) are visible as an outer ring region while ICAM-1/LFA-1 
complexes (Signal-2) form an inner region of the synapse. During T-cell activation, the TCR/MHC-
peptide complexes (Signal-1) move to the inner region, to form the central zone supra-molecular 
activation complex (cSMAC), and the ICAM-1/LFA-1 clusters form an outer ring called the peripheral 
zone supra-molecular activation complex (pSMAC) [3, 4].  The formation of the "immunological 
synapse" takes several minutes, and the duration of this engagement is key to the signaling process 
[2].  
The type of co-stimulatory signal (Signal-2) can influence the activation and commitment of T-
cells for Th-1 or Th-2 differentiation. Inhibition of the interaction between CD28 and B7 blocks IL-4 
and IL-5 (Th2 cytokines) production, while blocking the interaction between ICAM-1 and LFA-1 
increases Th2 cytokine production [5]. Furthermore, co-stimulation by ICAM-1 strongly inhibits IL-10 
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production, which may favor the development of Th1 rather than Th2 cells [6]. In addition, inhibition 
of ICAM-1/LFA-1 interaction has been shown to suppress T-cell activation to prevent allograft 
rejection [7, 8] and insulin-dependent diabetes mellitus (IDDM) [9, 10]. Monoclonal antibodies 
(mAbs) to ICAM-1 and LFA-1 have been developed for treating autoimmune diseases such as 
rheumatoid arthritis [11, 12] and psoriasis [13, 14]. 
Previously, we have discovered that linear and cyclic peptides derived from the α- and β-
subunits of LFA-1 can inhibit homotypic and heterotypic T-cell adhesion as well as mixed lymphocyte 
reaction (MLR) [15, 16].  The α-subunit peptides were derived from the I-domain [17, 18] and the 
divalent cation-binding region of LFA-1 [18, 19].  A cyclic peptide (cLABL) from the I-domain, which 
bound to the D1 domain of ICAM-1 and ICAM-3 and was internalized by ICAM-1 into the cytoplasmic 
domain, was identified [17]. Peptides derived from the divalent cation-binding region of the α-
subunit were found to inhibit homotypic T-cell adhesion and could complex with calcium and 
magnesium ions as in the LFA-1 receptor [19].  Finally, β2-subunit-derived peptides can bind to 
ICAM-1 and inhibit homotypic T-cell adhesion and suppress MLR [15, 16]. Interestingly, a β-subunit 
peptide, LBE, was found to enhance the binding of cLABL peptide to ICAM-1 [20]. This result 
suggested that the LBE peptide may change the conformation of ICAM-1 so that its affinity for cLABL 
peptide is higher.  
We also discovered linear and cyclic peptides derived from ICAM-1 that can inhibit ICAM-1/LFA-
1-mediated T-cell adhesion [15, 16, 18]. Linear peptides (ICAM1-21 and ICAM25-50) derived from the 
D1-domain of ICAM-1 were found to inhibit homotypic T-cell adhesion and mixed lymphocyte 
reaction (MLR) [15]. ICAM1-21 peptide (called IB peptide) inhibits binding of anti-CD-11a antibody to 
LFA-1, suggesting that this peptide can bind the α-subunit of LFA-1 [18]. In contrast, anti-CD11a 
antibody binding was enhanced by ICAM25-50 peptide (called IE peptide), suggesting that this peptide 
binds to a different site on LFA-1, which may induce a conformational change within LFA-1 to a more 
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favorable one for antibody binding [18]. The ICAM1-21 was reduced to three overlapping sequence 
cyclic peptides: cIBL (ICAM1-10), cIBC (ICAM6-15), and cIBR (ICAM12-21). The cyclic peptides were also 
able to inhibit homotypic and heterotypic T-cell adhesion, presumably by binding to the α-subunit of 
LFA-1 [16].  However, the detailed mechanisms of binding of these peptides to LFA-1 on the surface 
of T-cells are not well characterized. 
In this report, we have studied the mechanism of binding of ICAM-11-21 peptide and cyclic 
peptides cIBL, cIBC, and cIBR (Table 1) to LFA-1. Our hypothesis is that the activity of these peptides 
is due to their ability to mimic the ICAM-1 interaction with LFA-1.  The site of ICAM-1 binding to LFA-
1 is the I-domain of the α-subunit [21]; this suggests that the binding site of these peptides may also 
be within the I-domain.  Furthermore, we hypothesize that the activity of ICAM-1 peptides in 
inhibiting T-cell adhesion is due to their ability to induce LFA-1 receptor internalization [22]. The 
internalization of an ICAM-1 peptide ligand by LFA-1 presents an attractive and novel drug delivery 
system to target reactive T-cells involved in autoimmune diseases such as rheumatoid arthritis and 
multiple sclerosis.  By conjugating a therapeutic drug to this small peptide, the drug would be 
targeted into the cells that express LFA-1 receptor, reducing indiscriminant activity of the drug and 
its potential side effects.   
 
METHODS AND MATERIALS 
Materials  
Phorbol ester (phorbol 12-myristate-13-acetate, PMA) was used to activate the cells, and was 
purchased from Sigma (St. Louis, MO). All peptides were purchased from Multiple Peptide System (San 
Diego, CA).  Membrane probe DiD was purchased from Molecular Probes (Eugene, OR).  Soluble ICAM-1 
(sICAM-1), full-length soluble LFA-1 (sLFA-1), and monoclonal antibodies (R3.1, R7.1, R15.7, TS2/4) were 
from Boehringer-Ingelheim (Ridgefield, CT). 
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Cell Culture 
MOLT-3 cells, a leukemia-derived human T-cell line, were purchased from ATCC (Rockville, MD), and 
SKW-3 cells were obtained from Boehringer-Ingelheim. The cells were propagated in RPMI-1640 media 
containing 10% v/v fetal bovine serum and penicillin/streptomycin (100 mg/L medium) and incubated at 
37°C with 95% humidity and 5% CO2.  As necessary, cells were activated with 10% v/v PMA-containing 
medium.  The final PMA concentration was 2 µM, and optimum activation was achieved after 16 h of 
incubation. 
 
FITC-labeled Peptides 
FITC-labeled peptides were synthesized using procedures previously developed in our laboratory 
[22]. The labeled peptides were purified by semi-preparative HPLC.  The pure products were identified 
by analytical HPLC and FAB-MS. 
For FITC-peptide-binding experiments, 1% (w/v) BSA was used to block the non-specific binding. The 
effect of BSA on the fluorescence intensity of FITC-labeled peptides was evaluated. FITC-peptides were 
dissolved in PBS and their fluorescence measured as a function of increasing concentrations of BSA 
added.  The change in fluorescence intensity leveled at approximately 1% BSA/PBS.   
 
ELISA Assays to Determine ICAM-1 Peptide/LFA-1 Binding 
The binding of ICAM-1 cyclic peptides (cIBL, cIBC, and cIBR) to sLFA-1 were measured using three 
different ELISA assays: (i) direct binding of FITC-labeled peptide to sLFA-1-coated wells, (ii) inhibition of 
FITC-labeled peptide binding to LFA-1 by its corresponding unlabeled peptide, and (iii) inhibition of FITC-
labeled peptide binding to LFA-1 by anti-LFA-1 antibody. For each experiment, the ELISA plates were 
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prepared using the following method.  Diluting buffer (DB), which consisted of Dulbecco’s PBS with 
calcium and magnesium, 2.0 mM MgCl2, and 0.1 mM phenylmethylsulfonyl fluoride (PMSF), was first 
used to dissolve both peptides and sLFA-1. Plates were coated with 50 µL of sLFA-1 at a concentration of 
10–20 µg/mL on 96-well MaxiSorp ImmunoPlates from NUNC (Roskilde, Denmark) and incubated for 30 
min at room temperature (RT). The plates were washed twice with 200 µL of DB supplemented with 2% 
BSA and then incubated with 2% BSA/DB for 30 min at 37ºC. 
For direct binding studies, 50 µL of FITC-labeled peptides at 40 µM or 50 µL of anti-CD11a mAbs 
(R3.1 and R7.1) at 5 µg/mL were added to the plate and incubated for 1 h at 37ºC. The plates were then 
washed twice with 200 µL of DB.  To detect CD11a mAb binding, 50 µL of PE-conjugated goat anti-
mouse secondary antibody was added at a 1:1000 dilution and incubated for 30 min at 37ºC.  These 
wells were then washed twice with 200 µL of DB.  The fluorescence of bound peptide and antibody was 
measured using a PerSeptive Biosystems CytoFluor (Series 4000) fluorescence plate reader. 
The second ELISA was performed to determine the effect, if any, of the FITC-moiety and the 
specificity of peptide binding to LFA-1 by inhibiting their binding using the respective unlabeled peptide.  
In this experiment, plates were coated with sLFA-1 and blocked with 2% BSA, as above. 50 µL of 
unlabeled peptide (cIBL, cIBC or cIBR) at different concentrations (133 µM, 400 µM, and 533 µM) was 
added to LFA-1 coated wells and incubated for 30 min at 37ºC.  The plate was then washed twice with 
DB. The corresponding FITC-labeled peptide was added to these wells followed by a 30 min incubation 
at 37ºC.  The plate was washed with DB and the fluorescence measured.  
A third ELISA was performed to determine the binding site of peptides cIBL, cIBC, and cIBR on LFA-1. 
In this experiment, LFA-1 coated plates were prepared as previously described (see above). Next, 50 µL 
of an anti-CD11a antibody (R3.1 at 10 µg/mL) that binds to the I-domain of LFA-1 was added to sLFA-1 
coated wells. Incubation for 30 min at 37ºC was followed by washing with 200 µL of DB.  FITC-labeled 
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peptides (50 µL) at a concentration of 40 µM were then added to the plate and allowed to incubate for 
30 min at 37ºC. The plate was washed with DB and the fluorescence intensity measured using the ELISA 
plate reader. FITC-labeled cLABL peptide that does not bind to LFA-1 was used as a negative control [24]. 
As a reference and positive control, the results from anti-CD11a mAb (R3.1) and FITC-peptide direct 
binding ELISA assay were plotted next to results from this ELISA to demonstrate relative reduction in 
binding to LFA-1. 
 
Confocal Microscopy of FTIC-cIBR Co-localized with Anti-LFA-1 (CD18) Antibody 
SKW-3 T-cells (150 µL at 1 × 106 cells/mL) were treated with 50 µL of FITC-cIBR (200 µM) for 1 h at 
4ºC and then spun and washed in the following manner to remove unbound peptide. T-cells were 
centrifuged for 3 min at 1800 rpm, and the supernatant was decanted. Cells were resuspended in 500 µL 
of PBS, and they were centrifuged followed by removal of the supernatant.  The cells were then 
resuspended in 150 µL of PBS/1% BSA followed by addition of 50 µL of R15.7 (10 µg/L), an anti-LFA-1 
antibody to the β-chain of LFA-1. The cells were incubated with the antibody for 45 min at 4ºC, and then 
washed as before. Anti-LFA-1 antibody was detected with R-phycoerythrin (PE)-labeled goat-anti-mouse 
antibodies in the following manner.  PE-labeled secondary goat anti-mouse mAb (50 µL) was added (at a 
stock dilution of 1:50 in PBS/1% BSA/0.1% sodium azide) and allowed to incubate for 30 min at 4ºC. The 
cells were washed as described previously, resuspended in 2% paraformaldhyde in PBS, and kept at 4ºC 
until mounted.  The cells were mounted onto microscope slides by spinning at 400 rpm for 4 min in a 
Shandon Cytospin 3; a coverslip was then applied to protect the cells. A Ziess LSM510 confocal 
microscope with an argon ion laser and 2 HeNe lasers was used to visualize cells, and the PE and FITC 
fluorophores were excited at λ = 488 nm and read with a λ = 505–530 nm using a BP filter. 
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Confocal Microscopy of FTIC-peptide Internalization  
SKW-3 cells (150 µL at 1 × 106 cells/mL) were treated with 50 µL of FITC-cIBR (200 µM) for 1.5 h at 
either 37 or 4ºC.   Cells were then washed as previously described and resuspended in 2% 
paraformaldehyde in PBS.  Membrane probe DiD from Molecular Probes (Eugene, OR) was then added 
to a final concentration of 10 µM to label the cell membranes, and cells were kept at 4ºC until mounted 
on slides. FITC-cIBR was excited as described previously; however, the DiD membrane probe was excited 
at λ = 644 nm with emission at 665 nm.  Software used for multi-track 2-color specimens was provided 
by Zeiss LSM V2.8.  Z-sections through cell clusters were made at 0.4 µM intervals.    
 
BIACORE and TIRF Assays 
All surface plasmon resonance (SPR) experiments were conducted on a Biacore-1000 instrument 
from Biacore (Piscataway, NJ).  The LFA-1/ICAM-1 interaction was evaluated by immobilizing soluble 
LFA-1 with TS2/4 mAb.  The TS2/4 mAb was immobilized to the chip by the amine-coupling procedure.  
Briefly, a carboxymethyl-cellulose surface (MC5 chip purchased from Biacore) was activated with 
EDC/NHS for 7 min according to the manufacturer's protocol.  TS2/4 mAb at 50 µg/mL in 10 mM sodium 
acetate at pH 4.5 was then injected over the activated surface for 8 min at a rate of 5 µL/min.  The 
surface was blocked with 1.0 M ethanolamine.  This protocol resulted in approximately 3000 to 4000 
resonance units (RU) of immobilized mAb.  sLFA-1 at 50 µg/mL in 10 mM Tris and 1.0 to 2.0 mM MgCl2 
at pH 7.5 was adsorbed on to the TS2/4 mAb surface at a flow rate of 2.0 µL/min until saturation was 
achieved (~1000 RU).  
The inhibition experiments were conducted in buffer consisting of the following reagents: 10 mM 
Tris, 150 mM NaCl, and 1.0 to 2.0 mM MgCl2 at pH 7.5. Peptides were dissolved in running buffer at 
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concentrations of 100 µM and 1.0 mM. As a positive control, 15 µL of sICAM-1 (1.0 µM) was injected at 
15 µL/min. For inhibition experiments, 15 µL of peptide (100 µM and 1.0 mM) was injected 
simultaneously with sICAM-1 (1.0 µM) at a rate of 15 µL/min over the surface of LFA-1.  Evidence of LFA-
1/ICAM-1 inhibition is derived from the differences between the dissociation slopes (kd) of the 
sensograms after the injection of sICAM-1 with peptide compared to sICAM-1 alone.  An increase in the 
dissociation slope of peptide/sICAM-1 compared to sICAM-1 alone would be evidence that LFA-1/ICAM-
1 binding is blocked.  Sensograms were collected and evaluated using the BIAevaluation software from 
Biacore (Piscataway, NJ).   
 
RESULTS 
Binding of ICAM-1 cyclic peptides (cIBL, cIBC, and cIBR ) to LFA-1 
 
A series of ELISA assays was used to investigate the binding of ICAM-1-derived peptides to sLFA-1.  
Direct binding of FITC-labeled peptides  (FITC-cIBL, FITC-cIBC, and FITC-cIBR) to ELISA plates coated with 
sLFA-1 is shown in Figure 1A (open bars).  The binding affinity of FITC-labeled peptides to sLFA-1 is in the 
following order: FITC-cIBR > FITC-cIBC > FITC-cIBL.  FITC-labeled cLABL was used as a negative control. 
This peptide, which was derived from the I-domain of LFA-1, binds to domain-1 (D1) of ICAM-1.  This 
negative control peptide has a very weak binding to the LFA-1-coated plate, suggesting nonspecific 
interaction with the LFA-1 receptor. As a positive control, anti-LFA-1 mAbs R3.1 and R7.1 (10 µg/mL) 
were used (Figure 1A, gray bars).  Peptide cIBC, which has an overlapping sequence with cIBR, has 
slightly less affinity for LFA-1 than cIBR. cIBL has no sequence overlap with cIBR and shows the weakest 
affinity for LFA-1.  These results suggest that the overlapping sequence between cIBR and cIBC 
contributes to the binding of these peptides. 
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The binding site of ICAM-1 peptides on sLFA-1 was evaluated by blocking FITC-labeled peptide 
binding with an anti-CD11a mAb (R3.1), which binds to the I-domain of LFA-1. Figure 1A (black bars) 
shows that R3.1 mAb can block the binding of FITC-cIBL, FITC-cIBC, and FITC-cIBR to LFA-1.  As a negative 
control, the antibody did not block the nonspecific binding of FITC-cLABL. The binding of anti-LFA-1 
antibody (R3.1) to sLFA-1 is shown as a reference to demonstrate the affinity of the antibody for sLFA-1. 
These results suggest that all three ICAM-1 peptides bind to the I-domain of LFA-1, but cIBR peptide 
demonstrates more binding site overlap with the R3.1 antibody than do the cIBC or cIBL peptides.  
To evaluate the binding specificity of the FITC-labeled peptide for sLFA-1, the respective unlabeled 
peptide was used to block binding of FITC-labeled peptide to LFA-1 (Figure 1B). Different concentrations 
(133, 400, and 533 µM) of unlabeled peptides were incubated in sLFA-1 coated wells, and the plates 
were washed to remove unbound peptides. Then, the corresponding FITC-labeled peptide was added to 
the well. Figure 1B shows that the unlabeled ICAM-1 peptide can block binding of the FITC-labeled 
peptide to LFA-1 in a dose-dependent manner. However, the decrease in fluorescence does not 
correspond linearly to the concentration of  unlabeled peptide added.  This may suggest that secondary 
peptide-peptide interaction may occur at higher doses affecting the binding of the FITC-labeled peptide 
to LFA-1.  As a negative control, the unlabeled cLABL peptide did not block the binding of FITC-cLABL, 
suggesting that its binding was nonspecific.  Taken together, these results suggest that FITC-labeled 
peptides bind to the same site as the unlabeled peptide and that the FITC- group did not interfere with 
peptide binding. 
  
Peptide Binding and Internalization Properties on T-cells 
Although we have demonstrated that these peptides can bind sLFA-1 and inhibit binding of mAb to 
the I-domain of LFA-1, their ability to bind LFA-1 on the surface of T-cells was still in question.  
Therefore, using co-localization studies, the direct binding between the peptide and LFA-1 on the cell 
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surface can be demonstrated.  FITC-cIBR peptide was co-localized with anti-CD18 mAb (R15.7; anti-β-
subunit) of LFA-1 on SKW-3 cells. Previously, the cIBR peptide had been shown not to inhibit anti-CD18 
mAb-binding to LFA-1, suggesting that this peptide did not bind to the β-subunit. The peptide-antibody 
co-localization was followed by confocal microscopy. Figure 2 shows that FITC-cIBR (green) and R15.7 
mAb (red) are bound in close proximity at the cell surface in clusters that result in the apparent yellow 
color at the cell edge due to the overlap of both red and green fluorescence.  An especially bright yellow 
spot can be seen at the contact point between T-cells where a cluster of LFA-1 receptors interacts with 
the peptide.  Furthermore, because this image was taken at some depth within the cell, small spots of 
green fluorescence can be identified throughout the T-cell cytoplasm; these were later identified as 
internalized FITC-cIBR by scanning through the entire cell cytoplasm in 0.4 M increments using confocal 
microscopy.  
To evaluate the potential internalization of the peptides by LFA-1 receptors, temperature-
dependence binding studies were performed using FITC-cIBR, FITC-cIBC, and FITC-cIBL and were 
evaluated by flow cytometry (Figure 3). The binding of FTIC-labeled peptides to activated T-cells 
depends on the incubation time. The binding of FITC-cIBR plateaus at 60 min (Figure 3C), and FITC-cIBL 
at 120 min (Figure 3A). In contrast, FITC-cIBC binding does not appear to reach a plateau after 240 min 
of incubation time (Figure 3B). On the basis of the maximum fluorescence, the binding affinity of FITC-
labeled peptides to LFA-1 on T-cells at 37ºC is in the following order: FITC-cIBR>FITC-cIBC>FITC-cIBL. This 
order is similar to that observed for the peptide binding to sLFA-1 using ELISA.  T-cells treated with FITC-
labeled peptides at 37ºC have fluorescence intensities 5–8-fold greater than those treated at 4ºC 
(Figures 3A, B, and C). The results suggest that the fluorescence intensity at 37ºC was due to the surface 
binding and internalization of the FITC-labeled peptide. On the other hand, the fluorescence intensity at 
4ºC was due only to surface binding because, at this temperature, the receptor-mediated, energy-
dependent process of internalization was restricted. 
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To test the hypothesis that the FITC-labeled peptide can be internalized by LFA-1, confocal 
microscopy was used to evaluate the effect of temperature on FITC-cIBR peptide binding and 
internalization. In this study, SKW-3 T-cells were incubated with FTIC-cIBR peptide at either 37ºC or 4ºC 
(Figure 4). The cell membranes were stained with DiD (red color), which quenched the fluorescence of 
membrane-bound FITC-cIBR. A series of confocal microscope images of 0.4 µM Z-sections through a 
cluster of SKW-3 T-cells were recorded at both 37ºC and 4ºC (Figure 4). The results show that FITC-cIBR 
(green fluorescence) could be identified throughout the cytoplasm of cells that were treated at 37ºC 
(Figure 4B).  In contrast, there was no green fluorescence found inside the cells that were treated at 4ºC 
(Figure 4A).  These results strongly indicate that FITC-cIBR peptide binds to and is internalized by the 
LFA-1 receptors on T-cells at 37ºC. 
 
Biacore and TIRF Assays 
The ability of ICAM-1 peptides to inhibit binding of soluble ICAM-1 (sICAM-1) to sLFA-1 immobilized 
onto SPR chips was evaluated by both Biacore and TIRF assays.  As a standard and control, sICAM-1 was 
first injected onto the chip for a period of time to reach equilibrium binding with sLFA-1. After injection 
of sICAM-1, the Biacore or TIRF signal decreases, indicating the dissociation of LFA-1-bound sICAM-1 
from the chip surface.  The off rate (slope) of bound ICAM-1 was used as a reference to determine 
whether ICAM-1-derived peptides were able to inhibit sICAM-1 binding.  We expected to observe a 
faster off rate for sICAM-1 than for control if the ICAM-1-derived peptides bound to the sLFA-1 chip and 
blocked sICAM-1 from binding.   However, we found that these peptides did not alter the off rate of 
sICAM-1 in either the Biacore or TIFR assays. These results suggest that the peptide cannot inhibit the 
binding of sICAM-1 to immobilized LFA-1, however several factors may influence their activity in these 
assays. First, because purified LFA-1 constitutively exists in its high affinity form, this may affect the 
ability of these peptides to bind.  Also, because sLFA-1 is immobilized to the chip via the TS2/4 anti-LFA-
1 antibody, this may limit or restrain conformational changes of LFA-1 that may occur upon peptide 
binding. Second, it is unclear whether the high avidity form of LFA-1, characterized by receptor 
clustering on the cell surface is represented on the Biacore chip surface. In this in vitro environment, 
sICAM-1 may therefore bind to sLFA-1 in a slightly different manner than which it would on the cell 
surface. Therefore, the inability of these peptides to block sLFA-1/sICAM-1 interaction may not 
representative of their activity at the cellular level to inhibit LFA-1/ICAM-1 interaction. 
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DISCUSSION 
This study was designed to characterize the binding of cyclic ICAM-1 peptides (cIBL, cIBC, and cIBR) 
and LFA-1 on the surface of T-cells (see Table I). These cyclic peptides have overlapping sequences that 
are derived from ICAM-11-21 peptide (IB peptide). Cyclization of cIBL, cIBC and cIBR peptides was 
accomplished by the formation of a disulfide bond from the Pen1 to the Cys12 residues. Peptide 
cyclization stabilizes its conformation to a form that may enhance the specificity of the peptide for 
binding to LFA-1. These cyclic peptides (cIBL, cIBC, and cIBR) were found to inhibit homotypic T-cell 
adhesion as well as heterotypic T-cell adhesion to Caco-2 cell monolayers better than the parent IB 
peptide. However, previous studies presented no direct evidence to show that these cyclic peptides bind 
LFA-1.  
In the work presented here, the binding of cyclic peptides (cIBL, cIBC, and cIBR) to the LFA-1 
receptor was confirmed using (i) direct binding of FITC-labeled peptides to sLFA-1 receptors, (ii) 
inhibition of FITC-labeled peptide-binding to LFA-1 by an anti-CD11a mAb, (iii) co-localization of FITC-
cIBR peptide and anti-CD18 mAb to LFA-1 on T-cells, and (iv) temperature-dependent binding of FITC-
labeled peptide to T-cells. The order of binding affinity of the cyclic peptides to LFA-1 is as follows: FITC-
cIBR> FITC-cIBC> FITC-cIBL (Figure 1A, open bars). The binding of these peptides to LFA-1 can be 
inhibited by the binding of anti-CD11a mAb (R3.1) to the I-domain, suggesting that these peptides bind 
to the I-domain of LFA-1 (Figure 1A, filled bars).  Fluorescent microscopy images demonstrated that 
FITC-cIBR peptide (green) co-localized with a PE-anti-CD18 mAb (red) to give a yellow image on the 
surface of SKW-3 T-cells (Figure 2). These results suggest that the FITC-cIBR peptide binds to the α-
subunit of LFA-1 at the I-domain. 
The cyclic peptides (cIBL, cIBC, and cIBR) were derived from the A, A' and B strands of the ABED face 
of the D1 of ICAM-1 (Figure 5) [25, 26]. Previously, mutation studies suggested that ICAM-1 binds to the 
I-domain of LFA-1 via its GFC face through the Glu-34 residue. Furthermore, it has been also suggested 
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that ICAM-1 binding to LFA-1 utilizes non-linear epitopes [27].  However, others have shown that ICAM-
3 utilizes both the ABED and GFC face to bind LFA-1 [28]. Our results support this type of binding 
scenario because these peptides, whose sequences are found on this ABED face, also bound to the I-
domain.  Although ICAM-1 and ICAM-3 have distinct binding sites, there is much similarity between the 
binding sites of these two ligands to LFA-1. Furthermore, LFA-1 interaction with ICAM-3 is essential for 
LFA-1/ICAM-1-dependent adhesion and signal transduction during the initiation of an immune response 
[29].  Therefore, the unique interaction of ICAM-3 with LFA-1 through the ABED and GFC faces may 
induce receptor signaling different from that of ICAM-1 and may facilitate the specific function of ICAM-
3. 
The binding affinity of cIBR and cIBC peptides to LFA-1 is higher than that of the cIBL peptide; 
the cIBR and cIBC peptides have an overlapping Pro-Arg-Gly-Gly (PRGG) sequence with a β-turn 
structure [30, 31]. This epitope has a similar β-turn conformation in the X-ray structure of D1 of 
ICAM-1 (Figure 5). Alanine scanning also showed that this PRGG sequence is important for peptide 
activity (data not shown).  The presence of this β-turn structure could stabilize the peptide 
interaction with the I-domain of LFA-1.  Other studies have demonstrated the importance of proline 
residues flanking the RGD sequence. It is thought that proline may contribute to maintaining a 
favorable conformation for the solvent-exposed RGD site for its recognition by integrins [32]. 
In resting T-cells, LFA-1 is expressed in a low affinity state for ICAM-1; upon activation, the LFA-1 
changes conformation to a high affinity state.  The LFA-1 I-domain has been shown to bind ICAM-1 
at the metal ion-dependent adhesion site (MIDAS) by facilitating the interaction between LFA-1 
residues coordinating a divalent cation (Mn2+/Mg2+) and ICAM-1 residues [33, 34].  When Mg2+ is 
bound within the I-domain, a conformational change results in the C-terminal α7 helix swinging 
away from the central β-sheet.  This form is referred to as the opened (high affinity) form of LFA-1 
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[35]. However, it has been suggested that Ca2+ is bound to the MIDAS; it inhibits the expression of 
the high affinity form of LFA-1 and restrains LFA-1 conformation in the closed form.  LFA-1 affinity 
for ICAM-1 can also be controlled by small molecules, which bind to an allosteric control site called 
the I-domain allosteric site (IDAS) [35, 36]. These small molecule antagonists, such as statins, p-
arylthio cinnamides and hydantoin derivatives, are thought to prevent the conformational change 
from the closed to the open form of LFA-1 [36, 37].  Further studies have demonstrated that the 
binding of our ICAM-1 derived peptides to T-cells is enhanced by the presence of Ca2+, suggesting 
that peptide binding favors the closed conformation of LFA-1.  It may also suggest possible 
activation-dependent activity (data not shown).    
The isolated sLFA-1 receptor used in the Biascore assays is in the high affinity form, limiting the 
dynamic conformational changes of LFA-1 from closed to open. Therefore, these peptides’ 
activation-dependent sensitivity to the conformation of LFA-1 may explain why these peptides were 
not able to inhibit sLFA-1/sICAM-1 interaction in Biacore experiments. 
Internalization of ligand-bound integrins is a mechanism used to control a number of cellular 
processes. For example, β2-integrins may participate in regulating neutrophil adhesiveness by removing 
activated receptors or permitting receptor recycling [38]. The kinetics and morphology of endocytosis of 
mammalian cell integrin receptors have been studied using flow cytometry and, like our observations of 
the internalization of FITC-cIBR peptide, the internalization of integrin-ligand complexes was also 
dependent on temperature [39]. Many viruses are known to ‘high-jack’ integrins to mediate their entry 
into cells, and RGD-peptide ligands of integrins have been utilized to mediate gene delivery in synthetic 
and viral vector systems. Anti-viral therapies are also being developed based on peptide ligands for 
integrins. The HIV-1 virus uses the ICAM-1/LFA-1 interaction for entry into T-cells [40], and peptides 
derived from ICAM-1 (D1) were able to inhibit HIV-1 entry [41]. 
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While temperature-dependence studies alone are not unequivocal evidence of FITC-peptide 
internalization, further evidence of their internalization was confirmed  by flow cytometry and confocal 
microscopy studies. Incubation of the FITC-labeled cyclic peptides on T-cells at 37ºC shows a time-
dependent increase in fluorescence intensity; incubation at 4ºC does not show this increase (Figure 3). 
This result indicates that the FITC-labeled peptides are internalized by LFA-1, because cell metabolism 
and receptor-mediated internalization are negligible at 4ºC.  To prove this concept, we studied the 
internalization of FITC-cIBR peptide using confocal microscopy at 37ºC and 4ºC (Figure 4).  The 
membranes of T-cells were labeled with DiD (red), which quenches the fluorescence from the 
membrane-bound FITC-cIBR peptide (green).  Cross-sections of the confocal microscopy images of T-
cells incubated with FITC-cIBR peptide at 37ºC demonstrate the presence of green fluorescence in the 
cytoplasm (Figure 4), while cells incubated at 4ºC did not show green fluorescence in the cytoplasm.  
This result strongly indicates that the peptide was internalized by the LFA-1 receptor into the 
cytoplasmic domain of T-cells. The internalization of LFA-1 upon binding to peptides raises the possibility 
of another mechanism for these peptides to inhibit T-cell adhesion. The inhibition of T-cell adhesion 
could be due to the internalization of LFA-1 that is mediated by binding of ICAM-1 peptide.  This 
mechanism could be an alternative to the direct inhibition of ICAM-1 binding to LFA-1 by peptide 
blocking the binding site of ICAM-1 on LFA-1.  In the future, it would be interesting to evaluate this 
hypothesis by determining if there was a correlation between an increase in T-cell adhesion an LFA-1 re-
expression after peptide internalization.  
 
CONCLUSION 
We have shown that cIBL, cIBC, and cIBR peptides can bind to the I-domain of LFA-1 in isolated LFA-
1 as well as on the surface of T-cells.  These peptides were internalized by LFA-1 on T-cells, suggesting 
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that they can be utilized to target drugs to the cytoplasmic domain of T-cells. In the future, we will show 
the utility of these peptides in delivering cytotoxic drugs to T-cells. 
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Table I.  The sequences of ICAM-1-peptides that are used in this study. 
 
Peptide Name Sequence 
Number 
Amino Acid Sequence MW 
(g/mol) 
IB ICAM-11-21 QTSVSPSKVILPRGGSVLVTG 2082.2 
cIBLa ICAM-11-10 Cyclo(1,12)-Pen-QTSVSPSKVIC-OH 1667.6 
cIBCa ICAM-16-15 Cyclo(1,12)-Pen-PSKVILPRGGC-OH 1227.6 
cIBRa ICAM-112-21 Cyclo(1,12)-Pen-PRGGSVLVTGC-OH 1174.5 
cLABLa LFA-1237-247 Cyclo(1,12)-Pen-ITDGEATDSGC-OH 1197.5 
FITC-cIBLb ICAM-11-10 FITC-Cyclo(1,12)-Pen-QTSVSPSKVIC-OH 2057.5 
FITC-cIBCb ICAM-16-15 FITC-Cyclo(1,12)-Pen-PSKVILPRGGC-OH 1729.0 
FITC-cIBRb ICAM-112-21 FITC-Cyclo(1,12)-Pen-PRGGSVLVTGC-OH 1563.4 
FITC-cLABLb LFA-1237-247 FITC-Cyclo(1,12)-Pen-ITDGEATDSGC-OH 1587.4 
a) The formation of cyclic peptide was done by forming a disulfide bond between the penicillamine-1 
(Pen-1) and the cysteine-12 (Cys-12) residues.   Residues 2 through 11 were derived from the ICAM-1 
sequence. 
b) The FITC-label was conjugated to N-terminal of the peptide. 
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FIGURE LEGENDS 
 
Figure 1. (A) Binding properties of FITC-labeled cyclic peptides (FITC-cIBL, FITC-cIBC, and FITC-cIBR) to 
sLFA-1-coated wells relative to FITC-cLABL (open bars). Anti-LFA-1 antibodies (R3.1 and R7.1; 
hashed bars) were used as positive controls. Inhibition of FITC-labeled cyclic peptides 
binding to sLFA-1 by anti-LFA-1 antibodies (R3.1; filled bars). (B) Binding specificity of FITC-
labeled cyclic peptides to sLFA-1 demonstrated by their inhibition using increasing 
concentrations of the respective unlabeled peptides (cIBL, cIBC, and cIBR). *Denotes these 
values are not significantly different from each other 
 
Figure 2. Confocal microscopy image of the co-localization of FITC-cIBR (green) with an anti-CD18 
mAb (R15.7; red) on LFA-1 on the surface of SKW-3 T-cells. The co-localization of FITC-cIBR 
and anti-CD18 on LFA-1 receptors gives yellow image.    
 
Figure 3. Binding of FITC-labeled cyclic peptides to T-cells at 37ºC (open bars) and 4ºC (filled bars) as a 
function of time; the binding property was determined by flow cytometry: (A) FITC-cIBL; (B) 
FITC-cIBC; (C).FITC-cIBR  
 
Figure 4. Confocal microscopy images of SKW-3 T-cells after incubation of FITC-cIBR and membrane 
probe DiD at 37ºC (A) and 4ºC (B). In both A and B, each frame represents images taken at 
increasing depths of 0.4 µm within a cluster of SKW-3 T-cells. 
 
Figure 5. X-ray crystal structure of ICAM-1 domain-1 (D1) [25, 26] and the NMR structure of cIBR 
peptide (magenta) [30]. The cIBL, cIBC, and cIBR peptides are located along the face of the 
A, A’ and B strands on D1 of ICAM-1. The sequence of cIBR peptide in D1 of ICAM-1 is 
highlighted in magenta and the β-turn sequence (PRGG) is identified with arrows.  
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